Principal Financial Group Inc. Trims Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Principal Financial Group Inc. lowered its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 52.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,364 shares of the company’s stock after selling 13,417 shares during the period. Principal Financial Group Inc.’s holdings in Sana Biotechnology were worth $51,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Sana Biotechnology by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock valued at $121,552,000 after acquiring an additional 2,358,089 shares during the last quarter. Integral Health Asset Management LLC increased its position in Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares during the last quarter. Zimmer Partners LP purchased a new position in Sana Biotechnology during the first quarter worth approximately $2,025,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Sana Biotechnology by 2.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock valued at $36,956,000 after purchasing an additional 101,434 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Sana Biotechnology by 318.8% in the 2nd quarter. Squarepoint Ops LLC now owns 126,572 shares of the company’s stock valued at $691,000 after purchasing an additional 96,348 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Trading Down 1.2 %

NASDAQ:SANA opened at $2.45 on Wednesday. The firm’s fifty day simple moving average is $3.65 and its 200 day simple moving average is $5.24. Sana Biotechnology, Inc. has a twelve month low of $2.29 and a twelve month high of $12.00. The firm has a market capitalization of $547.01 million, a price-to-earnings ratio of -1.75 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. On average, analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 31.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on SANA. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Sana Biotechnology in a report on Monday, November 11th.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.